Pfizer Inc reported 17 positions worth $170.37M for the quarter ended Jun 30, 2026, down 28.7% on the prior quarter. It opened 0 new positions, added to 0, trimmed 3 and exited 1. Its largest holding is Allogene Therapeutics, Inc. at 27.5% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
No positions were added to this quarter.
No new positions this quarter.
| Holding | Shares Sold | Trade Value | Prior Weight |
|---|---|---|---|
| QTTB Q32 Bio Inc. | -101.6K | $736.73K | 0.309% |
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | ALLO Allogene Therapeutics, Inc. | Healthcare | 22.03M | $46.93M | 27.55% | 0 | 0.0% | Unchanged | 6.38% |
| 2 | CELC Celcuity Inc. | Healthcare | 295.7K | $29.55M | 17.35% | 0 | 0.0% | Unchanged | 0.54% |
| 3 | ARVN Arvinas, Inc. | Healthcare | 3.46M | $27.66M | 16.24% | 0 | 0.0% | Unchanged | 5.3% |
| 4 | PYXS Pyxis Oncology, Inc. | Healthcare | 7.03M | $19.48M | 11.43% | 0 | 0.0% | Unchanged | 10.99% |
| 5 | WVE Wave Life Sciences, Inc. | Healthcare | 1.88M | $10.93M | 6.42% | 0 | 0.0% | Unchanged | 0.92% |
| 6 | BHVN Biohaven Ltd. | Healthcare | 505.6K | $8.00M | 4.7% | 0 | 0.0% | Unchanged | 0.33% |
| 7 | CRBU Caribou Biosciences, Inc. | Healthcare | 4.69M | $7.88M | 4.63% | 0 | 0.0% | Unchanged | 4.43% |
| 8 | SPRO Spero Therapeutics, Inc. | Healthcare | 2.36M | $5.34M | 3.13% | 0 | 0.0% | Unchanged | 4.06% |
| 9 | ZNTL Zentalis Pharmaceuticals, Inc. | Healthcare | 953.8K | $3.85M | 2.26% | 0 | 0.0% | Unchanged | 1.33% |
| 10 | ORIC Oric Pharmaceuticals, Inc. | Healthcare | 372.9K | $3.55M | 2.09% | -4.41M | -92.2% | Reduced | 0.35% |
| 11 | CRDF Cardiff Oncology, Inc. | Healthcare | 2.41M | $3.01M | 1.77% | 0 | 0.0% | Unchanged | 3.52% |
| 12 | ZURA Zura Bio Ltd | Healthcare | 538.8K | $2.88M | 1.69% | -2.30M | -81.0% | Reduced | 0.42% |
| 13 | AGMB AgomAb Therapeutics NV | Healthcare | 75.0K | $1.04M | 0.608% | 0 | 0.0% | Unchanged | 0.6% |
| 14 | BOLT Bolt Biotherapeutics, Inc. | Healthcare | 31.3K | $133.83K | 0.079% | 0 | 0.0% | Unchanged | 1.63% |
| 15 | NXTC NextCure, Inc. | Healthcare | 44.3K | $72.97K | 0.043% | -109.0K | -71.1% | Reduced | 0.84% |
Tip. Select a row to see that position’s full history at Pfizer.
As of its Q2 2026 13F filing, Pfizer Inc’s five largest positions were Allogene Therapeutics, Inc. (ALLO) at 27.5%, Celcuity Inc. (CELC) at 17.3%, Arvinas, Inc. (ARVN) at 16.2%, Pyxis Oncology, Inc. (PYXS) at 11.4%, Wave Life Sciences, Inc. (WVE) at 6.4% of the reported portfolio.
Pfizer Inc reported a 13F portfolio worth $170.37M across 17 positions for Q2 2026. That is down 28.7% from the previous quarter.
Its largest sales by value were Oric Pharmaceuticals, Inc. ($42.00M), Zura Bio Ltd ($12.31M), Q32 Bio Inc. ($736.73K). It exited 1 positions entirely.
From the Form 13F-HR reports Pfizer Inc files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.